Valeant swallows another company, buys Solta for $250m
This article was originally published in Clinica
Executive Summary
Valeant Pharmaceuticals will buy aesthetics device developer Solta Medical for $250m in only the third purchase for the acquisitive Canadian company this year. Then again, 2013 isn't over yet.